September 25, 2007 - Abbott Laboratories said it is working with the FDA Administration to schedule an advisory panel review Nov. 29, 2007, for the company’s Xience drug-coated stent heart device.

Any panel recommendations and follow-up decision from the FDA would also cover the Promus coated stent made by Boston Scientific Corp. because Promus and Xience are the same device, but are sold under different labels. Boston Scientific shares Promus profit with Abbott through an agreement reached last year when the two companies bought parts of Guidant Corp.

September 25, 2007 - Cordis Corp. today announced the introduction in the U.S. market of the FIRE STAR Rx PTCA Dilatation Catheter and the DURA STAR Rx PTCA Dilatation Catheter starting on Oct. 15, 2007, as the company builds its portfolio of products and services to support interventional cardiologists and cath lab teams.

September 25, 2007 - Abbott enrolled the first patient in HERCULES (Herculink Elite Cobalt Chromium Renal Stent Trial to Demonstrate Efficacy and Safety), a U.S. clinical trial designed to evaluate the safety and effectiveness of the investigational RX Herculink Elite Renal Stent System to treat patients with renal artery stenosis (RAS).

September 25, 2007 - The risk of developing venous thromboembolism while flying on an airplane, a condition known as “economy class syndrome,” is only about one in 5,000 for long flights, although the odds of in-flight clot are higher for some groups, according to a new study out of The Netherlands.

September 25, 2007 - The Medicines Company announced that the FDA has accepted its supplemental new drug application (sNDA) for a modified dosing regimen of Angiomax (bivalirudin) for the treatment of acute coronary syndromes (ACS), specifically in patients with unstable angina or non-segment elevation myocardial infarction (NSTEMI), which could replace heparin in patients undergoing angioplasty.

September 25, 2007 - The Sorin Group, a European cardiovascular company, announced today that it has received FDA clearance for marketing its MEMO 3D Semirigid Annuloplasty Ring in the U.S., targeting patients receiving mitral valve repair as therapy for mitral valve disease.

Annuloplasty rings are indicated for repair of the mitral valve and are designed to remodel the anatomical shape of the mitral annulus, preventing further dilatation and minimizing the risk of late repair failures.

The FIRE STAR Rx PTCA Dilatation Catheter and the DURA STAR Rx PTCA Dilatation Catheter are indicated for expansion in the narrowed area of a coronary artery or bypass graft. The FIRE STAR Balloon features the lowest pre-dilatation profile in the market.

September 24, 2007 - Stentys announced that its drug-eluting bifurcated stent for treatment of blocked coronary artery bifurcations was implanted in a patient, marking the first human implantation of the stent.

The implant was completed in reportedly routine interventional time, and the patient was released from the ICU within hours of the implantation of the Stentys bifurcated stent and was discharged from the hospital shortly after the procedure.

September 21, 2007 - Catheter angiography may be unnecessary in cases where the CT angiogram (CTA) is indeterminate for aortic injury, according to a study conducted by radiologists at the University of Washington and the Harborview Injury Prevention and Research Center in Seattle, WA.

September 21, 2007-The CYPHER Sirolimus-eluting Coronary Stent reduced by more than half the rate of major adverse cardiac events (MACE) compared to the Taxus Stent in small coronary vessels, according to data appearing this week in the Journal of the American College of Cardiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now